Oncology Venture acquires rights to shelved Novartis drug
Oncology Venture spin-out company utilizes its option to acquire the rights for a phase 3 cancer drug from Swiss Novartis.
Danish Oncology Venture utilizes a previously agreed option to take over the rights to develop and commercialize the cancer drug dovitinib (TKI258), which was originally developed by Novartis. Now it is jointly owned the Oncology Venture owned spin-out OV-SPV2, the parent company MPI and the co-investor Sass & Larsen Aps.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Biotech company acquires former Novartis drug
For abonnenter
Growing deficit in Oncology Venture
For abonnenter
Danish biotech merger to attract major investors
For abonnenter
